Veralox Therapeutics is a small molecule drug discovery and development company that is developing small molecule therapeutics for the purpose of treating the underlying pathologies of thrombosis and type 1 diabetes. Based on the understanding of the molecular mechanisms of the diseases, the efforts will turn to new treatment ways and better patients' outcomes.
Veralox is developing a disease-modifying therapy for Type 1 diabetes, another immune-driven pathology. In Type 1 diabetes patients, an abnormal immune response results in damage and destruction to insulin-producing pancreatic β-cells, inflammatory signals increase the expression of 12-LOX, leading to an overabundance of 12-HETE. 12-HETE stresses β-cells leading to a reduction in insulin production, by inhibiting 12-LOX in the pancreas and shutting down production of 12-HETE, insulin β-cells are preserved and able to function properly.
With a high number of T1D patients, particularly new-onset T1D patients having functional β-cells, the approach of Velarox is promising to sustain insulin production in these patients.